Urology

YOU ARE EXPLORING

Urologic Oncology

Urologic Oncology Fellowship

The Urologic Oncology Fellowship Program at Indiana University School of Medicine Department of Urology is a two-year program comprised of one research year followed by one year of clinical fellowship. Consistent with the mission of the Society of Urologic Oncology, the program provides comprehensive training in clinical genitourinary oncology through advanced surgical training, multidisciplinary didactics and clinical/translational research endeavors.

First Year Curriculum

During the first year, fellows participate in clinical, translational and basic science research. Research training covers protocol development and clinical trial design, collaboration and coordination of translational projects with researchers at Indiana University and Purdue University, and health services and outcomes-based study. Basic science research is focused on genetic and translational approaches to the treatment and management of urologic malignancies.

Opportunities to rotate with Department of Urology medical oncology and radiation oncology colleagues are coordinated during the year and fellows serve as a clinical staff at Sidney & Lois Eskenazi Hospital, participating in autonomous resident supervision and teaching. Overall clinical responsibilities during the first year of this fellowship program comprise less than 10 percent of the fellow’s time. The remaining time is protected for research and academic study.

Fellows are encouraged to present abstracts at regional and national meetings and contribute to peer-reviewed publications. They are responsible for leading a weekly multidisciplinary cancer conference and they attend many other conferences, including a monthly general urology research conference, monthly oncology journal club meetings, monthly fusion/focal therapy conferences and a weekly didactic lecture series.

Second Year Curriculum

The second year of this fellowship is dedicated to clinical training in the operating room. Fellows participate in a wide array of open and minimally invasive surgery procedures performed under the supervision of experienced urologic oncology faculty physicians. They receive high-volume surgical experience with complex oncologic exposure. The department’s teaching faculty have unparalleled clinical experience in complex oncologic and reconstructive surgery and are recognized globally for surgical expertise in testicular and advanced bladder cancer.

Average number of procedures per fellow:

  • Radical prostatectomy- 26
  • Radical cystectomy, conduit- 28
  • Radical cystectomy, continent diversion- 24
  • Pelvic exenteration with diversion- 6
  • Retroperitoneal lymph node dissection- 55
  • Radical nephrectomy- 30
  • Partial nephrectomy- 25
  • Adrenalectomy- 3
  • Urethrectomy- 3
  • Penectomy- 5
  • Inguinal lymph node dissection- 6

Active Research

  • A prospective program to reduce the clinical incidence of clostridium difficile colitis infection after radical cystectomy
  • Does carcinoma in-situ respond to cisplatin-based neoadjuvant chemotherapy
  • A novel pre-operative model to predict 90-day surgical mortality in patients considered for renal cell carcinoma surgery
  • Determining the metastatic potential of oncocytic neoplasms
  • Determining the growth rate of SRM on active surveillance stratified by histology
  • Outcomes in contemporary series of patients managed surgically for xanthogranulomatous pyelonephritis
  • Grade and stage concordance in patients with multifocal non-hereditary renal cell carcinoma
  • Use of MRI for local staging to plan surgical treatment
  • Long-term oncological outcomes in men undergoing radical prostatectomy for a Gleason score of eight or higher
  • Intraoperative nerve monitoring during robotic-assisted radical prostatectomy using the ProPep surgical nerve monitoring system
  • Does magnetic resonance imaging (MRI) targeted bx result in a more accurate prediction of final pathology after radical prostatectomy (upgrading/downgrading rates)
  • The impact of induction chemotherapy regimen on operative and pulmonary morbidity in patients with stage I good risk non-seminomatous germ cell tumor
  • Is alvimopan beneficial in patients diagnosed with testis cancer who require retroperitoneal lymph node dissection (RPLND).
  • Describing the oncological outcomes of patients with stage II sex-cord stromal tumors
  • Recurrence patterns after open RPLND

Teaching Faculty

Timothy A. Masterson, MD

Timothy A. Masterson, MD

Associate Professor of Urology
Clint D. Bahler, MD,  MS

Clint D. Bahler, MD, MS

Assistant Professor of Urology
Richard Bihrle, MD

Richard Bihrle, MD

Dr. Norbert M. Welch, Sr. and Louise A. Welch Professor Emeritus of Urology
Ronald S. Boris, MD

Ronald S. Boris, MD

Assistant Professor of Clinical Urology
Clint Cary, MD,  MPH

Clint Cary, MD, MPH

Assistant Professor of Urology
Richard S. Foster, MD

Richard S. Foster, MD

Professor of Urology
Tom Gardner, MD

Tom Gardner, MD

Professor of Urology
Hristos Z. Kaimakliotis, MD

Hristos Z. Kaimakliotis, MD

Assistant Professor of Urology
Michael O. Koch, MD

Michael O. Koch, MD

Chair, Department of Urology
Matthew J. Mellon, MD

Matthew J. Mellon, MD

Assistant Professor of Urology